Shattuck Labs (STTK) CEO exercises warrants to acquire 25,610 common shares

Rhea-AI Filing Summary

Shattuck Labs, Inc. director and Chief Executive Officer Taylor Schreiber reported acquiring 25,610 shares of common stock through the exercise of warrants at a conversion price of $1.0846 per share. Following these transactions, Schreiber holds 122,222 shares directly and 2,610,750 shares indirectly through Houghton Capital Holdings, LLC.

Insider Trade Summary

25,610 shares exercised/converted

Mixed 3 txns

Insider Schreiber Taylor

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Warrants (Right to Buy)	25,610	$0.00	--
Grant/Award	Common Stock	25,610	$1.0846	$28K
holding	Common Stock	--	--	--

Holdings After Transaction: Warrants (Right to Buy) — 0 shares (Direct, null); Common Stock — 122,222 shares (Direct, null); Common Stock — 2,610,750 shares (Indirect, By Houghton Capital Holdings, LLC)

Footnotes (1)

1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

Key Figures

Shares acquired via warrants: 25,610 shares Warrant conversion price: $1.0846 per share Direct holdings after transaction: 122,222 shares +3 more

6 metrics

Shares acquired via warrants 25,610 shares Warrant exercise on 2026-05-12

Warrant conversion price $1.0846 per share Exercise price for underlying common stock

Direct holdings after transaction 122,222 shares Common stock directly owned after Form 4 transactions

Indirect holdings after transaction 2,610,750 shares Common stock held indirectly via Houghton Capital Holdings, LLC

Private placement unit price $0.8677 per share and warrant Price under August 4, 2025 securities purchase agreement

Warrants exercised 25,610 warrants Derivative exercise converting into common stock

Key Terms

securities purchase agreement, private placement, Warrants, Phase 1 clinical trial, +1 more

5 terms

securities purchase agreement financial

"the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

private placement financial

"the Issuer in a private placement, which closed on August 25, 2025, issued and sold"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

Warrants financial

"accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Phase 1 clinical trial medical

"the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data"

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

Phase 2 clinical trial(s) medical

"and the design of the planned Phase 2 clinical trial(s) have been announced publicly"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schreiber Taylor

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TEXAS 78701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		A		25,610	A	$1.0846	122,222	D
Common Stock								2,610,750	I	By Houghton Capital Holdings, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$1.0846	05/12/2026		M			25,610	(2)	(2)	Common Stock	25,610	(1)	0	D

Explanation of Responses:

1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

	/s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Shattuck Labs (STTK) report for Taylor Schreiber?

Taylor Schreiber reported acquiring 25,610 shares of Shattuck Labs common stock. The acquisition came from exercising warrants into common shares at a stated conversion price, increasing his direct ownership position while also disclosing substantial indirect holdings.

How many Shattuck Labs (STTK) shares did the CEO acquire and at what price?

The CEO acquired 25,610 shares of Shattuck Labs common stock. These shares were obtained via warrant exercise with a conversion price of $1.0846 per share, reflecting a derivative conversion rather than an open-market purchase.

What are Taylor Schreiber’s total direct Shattuck Labs (STTK) holdings after the Form 4?

After the reported transactions, Taylor Schreiber directly holds 122,222 shares of Shattuck Labs common stock. This figure reflects his position immediately following the warrant exercise and related share acquisition disclosed in the Form 4 filing.

Does Taylor Schreiber have indirect ownership of Shattuck Labs (STTK) shares?

Yes. The Form 4 shows indirect ownership of 2,610,750 Shattuck Labs common shares. These shares are held through Houghton Capital Holdings, LLC, which is identified as the indirect owner in the filing under nature of ownership.

What is the background of the warrants exercised in the Shattuck Labs (STTK) Form 4?

The warrants relate to a private placement under an August 4, 2025 securities purchase agreement. Shattuck Labs sold 25,610 common shares and accompanying warrants at $0.8677 per share-and-warrant unit to certain accredited investors, including Taylor Schreiber.

When do the Shattuck Labs (STTK) warrants become exercisable according to the filing?

The warrants are exercisable at any time on or after their original issuance date. This continues until 30 days after Shattuck Labs publicly announces key Phase 1 SL-325 trial data and the design of planned Phase 2 clinical trial or trials.